FDA Warning Letters on Exosome Products | Regulatory & Criminal Defense

FDA warning letters to exosome manufacturers cite unapproved drugs, unlicensed biologics, and misbranded products under the FD&C Act and PHS Act. Analysis of enforcement trends from 2024 through 2026, criminal prosecution risks, and the regulatory framework for exosome products. Defense by former senior DOJ officials.